Overview
- Researchers isolated antibody 04_A06 from the blood of 32 elite controllers after screening 831 antibodies against 337 HIV-1 subtypes.
- In laboratory assays, 04_A06 neutralized more than 90–95% of tested HIV-1 variants and targets the virus’s CD4 binding site.
- In humanized mice infected with the HIV-1 YU2 strain, treatment with 04_A06 fully suppressed viral levels.
- A modeling analysis of an extended version projected over 93% protection if given three times within 24 weeks, which remains to be confirmed in people.
- The work was published in Nature Immunology, the University of Cologne filed a patent, and independent experts cautioned that the findings are preclinical.